Chronic Lymphocytic Leukaemia Clinical Trials

11 recruiting

Chronic Lymphocytic Leukaemia Trials at a Glance

9 actively recruiting trials for chronic lymphocytic leukaemia are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Milan, Madrid, and Barcelona. Lead sponsors running chronic lymphocytic leukaemia studies include Australasian Leukaemia and Lymphoma Group (ALLG), AstraZeneca, and Bristol-Myers Squibb.

Browse chronic lymphocytic leukaemia trials by phase

Treatments under study

About Chronic Lymphocytic Leukaemia Clinical Trials

Looking for clinical trials for Chronic Lymphocytic Leukaemia? There are currently 11 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Lymphocytic Leukaemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Lymphocytic Leukaemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 4

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Heart FailureChronic Lymphocytic Leukaemia
AstraZeneca60 enrolled23 locationsNCT06651970
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 1Phase 2

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

Small Lymphocytic LymphomaChronic Lymphocytic Leukaemia
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Non-Hodgkin LymphomaMultiple MyelomaChronic Lymphocytic Leukaemia
Bristol-Myers Squibb50 enrolled8 locationsNCT06357754
Recruiting
Phase 2

CLL11 - A study to evaluate the efficacy of Epcoritamab consolidation in high genomic risk and Measurable Residual Disease (MRD)-positive Chronic Lymphocytic Leukaemia (CLL) patients after first-line venetoclax and obinutuzumab

Chronic Lymphocytic Leukaemia
Australasian Leukaemia and Lymphoma Group (ALLG)38 enrolled1 locationACTRN12625000387426
Recruiting

Study on the Diagnosis and Management of CLL in Italy by GIMEMA

Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
Gruppo Italiano Malattie EMatologiche dell'Adulto12,500 enrolled24 locationsNCT04867915
Recruiting

Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project

Multiple Myeloma (MM)Chronic Lymphocytic Leukaemia (CLL)Secondary Immunodeficiency (SID)
Medical University Innsbruck120 enrolled5 locationsNCT06821880
Recruiting
Phase 2

CLL08 - A study to evaluate the efficacy of venetoclax/rituximab (VenR) re-treatment in relapsed/refractory Chronic Lymphocytic Leukaemia (CLL) patients with disease progression following VenR as their last line of therapy.

Chronic Lymphocytic Leukaemia
Australasian Leukaemia and Lymphoma Group (ALLG)80 enrolled1 locationACTRN12623000640606
Recruiting
Phase 1

Safety of Immune Cells for Patients with Relapsed Leukaemia or Lymphoma after Bone Marrow Transplant

Acute Lymphoblastic LeukaemiaNon-Hodgkins LymphomaChronic Lymphocytic Leukaemia
Western Sydney Local Health District, Westmead Hospital20 enrolled3 locationsACTRN12617001579381